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through the prism of surgical judgment. It is worth empha-
sizing that all risk models are derived from patients who
have actually undergone surgery; therefore, translating
these algorithms to populations previously never referred
for AVR may also limit their accuracy. Ultimately, the
simultaneous use of multiple models to generate a concor-
dant risk assessment will likely surpass the efficacy of any
individual model.
In terms of selecting patients for experimental therapies,
some underestimation of risk represents a more conserva-
tive approach than does overprediction. Overestimation
runs the risk of potentially recruiting patients for a treatment
of unknown durability who might do well with conventional
surgery with known efficacy and long-term results. Opera-
tive mortality has historically been the most important per-
formance parameter collected for patients having cardiac
surgery. It is an objective variable with little room for
ambiguity in data collection. However, for the elderly un-
dergoing AVR, improvement in quality of life becomes the
primary goal of surgical intervention as opposed to extend-
ing a diminished life expectancy. Transcatheter valve im-
plantation has the potential to decrease the morbidity asso-
ciated with standard AVR in a high-risk population owing
to the avoidance of a median sternotomy, cardiopulmonary
bypass, and cardioplegic arrest. Nevertheless, the selection
process necessitates thoughtful consideration of the short-
and long-term risks and benefits of the procedure and a
comparison of these factors with alternative therapies. Over-
reliance on individual risk algorithms may introduce bias
owing to the limitations of the model.
In summary, the STS-PROM appears to be the most
reliable single risk scoring model of those evaluated for
both perioperative mortality and long-term survival after
isolated AVR for AS in extremely high-risk patients. Patient
identification as high risk can differ widely between differ-
ent models on the basis of the variables collected and the
weighting used to calculate predicted mortality. Overesti-
mation of risk, especially when used to identify patients for
experimental treatment, may lead to inclusion of patients
who could do well with conventional approaches. Deter-
mining the appropriate break point in predicted risk that
confers candidacy for alternative approaches can be prob-
lematic given the illustrated limitations of these four com-
monly used algorithms. Surgical judgment should continue
to be used in conjunction with risk scoring to identify these
patients.
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Discussion
Dr Eugene H. Blackstone (Cleveland, Ohio). Dr Dewey, I con-
gratulate you and your colleagues on this particularly timely study.
Decisions are being made, at least temporarily, about appropriate
candidates for early trials of percutaneous AVR. Further, survival
after device placement is being compared with that expected were
open surgery performed using some of these algorithms. Your
study simultaneously addresses the issue of risk stratification to
identify the highest risk patients and risk calibration to quantify
expected risk. You paint a somewhat disturbing picture.
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As an aside, I particularly appreciate your recognizing that
early risk does not stop at hospital discharge or even at 30 days, but
extends further—in patients with complex problems sometimes
many months—a fact that none of these models accounts for
explicitly.
Your study is in the same vein as the one recently presented by
the Heidelberg group at the European Association. It augments it,
however, by looking at three algorithms for risk stratification and
expected survival rather than just at the EuroSCORE. Let me
highlight three findings of that group, because they lead to a
question about your study.
First, in the highest-risk patients, EuroSCORE greatly overes-
timated risk, just as you have found. This means that expected risk
is not well calibrated to actual risk and calls into question not just
which patient is at high risk but also any attempt to use estimated
risk as a barometer to assess observed risk of alternative proce-
dures.
Second, they found that calibration progressively worsened
with era of operation. The EuroSCORE was based on data from
1995; 10 years later, it should not be expected to be well calibrated
to contemporary results. It needs to be updated, as do some other
measures.
But third, they nevertheless found that as a tool to rank patients
according to risk, that is, risk stratification, performance remained
good.
So question one is, have you examined performance of these
scores across your experience in terms of both calibration to actual
risk and consistency in ranking patients?
Now, a different sort of observation I would like to make is
related to what today I would call prediction error, although in
earlier times I called it residual risk. When we examined prediction
error for time-related survival of nearly 4000 Belgian patients after
coronary artery bypass grafting, we found three categories of error:
(1) variables available but ignored that actually were associated
with risk, which is one of the points you make in your discussion;
(2) variables representing rare subgroups of patients not present in
sufficient abundance at time of model development to estimate risk
reliably; and (3) variables representing subgroups completely ab-
sent from the mix of patients on whom the model was developed.
It seems that you have identified all three of these pitfalls in
your study: ignored variables, variables related to unusual com-
plexity of frail, elderly patients being considered for alternative
therapy, and a subgroup of patients not represented in the mix of
open surgery patients for whom these models were developed.
This leads me to a second question followed by an observation:
What was the survival of patients who were identified concor-
dantly by all three algorithms and, as a corollary, what was the
survival of the discordant patients? I ask this to encourage you not
to be terribly discouraged by somewhat discordant results by three
or four different models. Indeed, I believe this points to the correct
direction for the future.
Here is what is going on in analysis of genetic data and a
number of other fields. Rather than developing a single model such
as a classification or risk stratification tree, thousands and even
tens of thousands of models are built from the data. Building from
a single classification tree to multiple forests of trees (based
completely on minimizing prediction error) may pave the way for
best identifying high-risk patients and possibly even best predict-
ing their expected survival. But it will work only if such patients
are already present in our databases or if we become really good,
as we are not now, at extrapolating beyond our data.
Dr Dewey. Thank you very much, Dr Blackstone, for your kind
comments and for taking your time to review our manuscript. As
usual, you find a unique way of looking at the data that others of
us have not quite thought about, and I think your comments are
actually very appropriate and cogent.
We have not examined the performance of these scores across
our entire experience, and we have not specifically looked at how
the patients identified by each of the algorithms, how their survival
compares with the ones who were not discordant within the algo-
rithms. One would assume that the patients in common, which
ranged to about 60% for the most part, are the ones that are dying,
and the reasons that there are differences either in perioperative
mortality or long-term follow-up is that the other risk algorithms
are diluted by other patients who do better than these truly higher-
risk patients.
Your comments in regard to updating and continually review-
ing these risk algorithms are particularly appropriate. The STS
algorithm patient set was defined from 1994 to 1997, and our
patient population may have actually changed over that time
period. That is a decade ago and probably need to be updated and
looked at to see how valid it is during this decade.
One of the tensions with these algorithms is that these are
designed to be used at the bedside as a simple sort of tool that
surgeons can use, so that when you go into the patient’s room and
talk to the patient, you have some numbers available other than
your experience or your gestalt. And while not ever going to be as
accurate as if you use multiple different algorithms based on much
larger data sets and variables, I think they are still relatively useful
for the tools in which we use them.
Dr Robert A. Guyton (Atlanta, Ga). That is a very nice study.
A recent presentation of Core Valve patients, 22 patients from
Germany, presented an LES score averaging 11%. When we used
the STS prediction to roughly estimate this predictive mortality, it
was more in the range of 6%. The LES data appeared to overes-
timate the risk, and these were patients undergoing percutaneous
valve procedures, with a 6% to 10% operative mortality based on
these predictions. On the basis of your study, would it be appro-
priate to recommend that patients being included in percutaneous
valve studies be assessed by more than one, perhaps at least three,
of the existing prediction systems so that we have a good idea of
what range of operative mortality that we are talking about in these
patients who are now undergoing percutaneous or transapical
therapy?
Dr Dewey. That is a very good comment, Dr Guyton. I think I
would be very careful about relying just on the LES, because I
think not only our study but also other studies show that in
high-risk patient populations it tends to overestimate risk. Now, I
would argue that an LES of 11 is not a high-risk population to
begin with. One of the areas that we have in the percutaneous valve
patients, however, is these are typically patients who have not had
surgery, theoretically, and so how you incorporate that patient set
into a pool of patients who had surgery in which these algorithms
were developed is somewhat tricky. Our risk algorithms may not
be nearly as applicable to those patients who might never have had
surgery as some of the patients that we are looking at currently.
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